Brief: Precision BioSciences Presents Phase 1 PBGENE-HBV Trial Data At HBV Cure Symposium; Targets Chronic Hepatitis B
12/09/2025 12:14
Sept 12 (Reuters) - Precision BioSciences Inc DTIL.O: PRECISION BIOSCIENCES PRESENTS DATA FROM THE PHASE 1 ELIMINATE-B TRIAL OF PBGENE-HBV AT THE 6TH INTERNATIONAL COALITION TO ELIMINATE HBV CURE SYMPOSIUM Source text: ID:nBw8x3gvGa Further company coverage: DTIL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing